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Atypical teratoid/rhabdoid tumor (AT/RT), which har-
bors SMARCB1 mutation and exhibits a character-
istic histology of rhabdoid cells, has a poor prognosis
because of the lack of effective treatments. Here,
we establish human SMARCB1-deficient pluripotent
stem cells (hPSCs). SMARCB1-deficient hPSC-
derived neural progenitor-like cells (NPLCs) efficiently
give rise to brain tumors when transplanted into the
mouse brain. Notably, activation of an embryonic
stem cell (ESC)-like signature confers a rhabdoid his-
tology in SMARCB1-deficient NPLC-derived tumors
and causes a poor prognosis. Consistently, we find
the activation of the ESC-like gene expression signa-
ture and an ESC-like DNA methylation landscape in
clinical specimens of AT/RT. Finally, we identify
candidate genes that maintain the activation of the
ESC-like signature and the growth of AT/RT cells.
Collectively, SMARCB1-deficient hPSCs offer the
human models for AT/RT, which uncover the role of
the activated ESC-like signature in the poor prognosis
and unique histology of AT/RT.
INTRODUCTION
Atypical teratoid/rhabdoid tumor (AT/RT) is an extraordinarily le-
thal malignant CNS tumor that occurs mainly in early childhood.
The representative morphological feature of AT/RT is a popula-
tion of cells with classic rhabdoid features: eccentrically located
nuclei containing vesicular chromatin, prominent eosinophilic
nucleoli, abundant cytoplasm with an obvious eosinophilic glob-
ular cytoplasmic inclusion, and well-defined cell borders (Louis
et al., 2016). Loss of SMARCB1 (also known as INI1, SNF5, or
BAF47) expression at the protein level is observed in almost all
AT/RTs, and current consensus holds that immunohistochem-
ical staining for SMARCB1 is a sensitive and specific test for
the diagnosis of AT/RT (Louis et al., 2016). Several mouse
models of Smarcb1 ablation have been developed to model
AT/RT and rhabdoid tumor (Ng et al., 2015; Han et al., 2016).
Genetic ablation of Smarcb1 at different developmental stages
revealed that intracranial tumors with the rhabdoid histology
develop only when Smarcb1 is deleted at embryonic day 6–10
(E6–E10), whereas ablation after birth results in lymphoma devel-
opment, indicating that a restricted early developmental window
is required for the initiation of intracranial rhabdoid tumors
(Han et al., 2016). Furthermore, compound deletion of Smarcb1
and p53 at GFAP-expressing neuronal progenitor cells resulted
in the development of AT/RT with rhabdoid histological features.
Moreover, the expression profile of mouse and human intracra-
nial rhabdoid tumors revealed the highest correlation with neural
progenitors and stem cells (Han et al., 2016). Taken together,
these findings suggest that AT/RT may arise from neural stem
or progenitor cells.
Patients with AT/RT show a rapid clinical deterioration and
extremely worse outcome than those with other CNS tumors,
despite aggressive surgical and adjuvant radiochemotherapy.
Retrospective and epidemiological studies have demonstrated
a mean overall survival ranging from 6 to 18 months (Hilden
et al., 2004; von Hoff et al., 2011; Chen et al., 2006). Although
intensive multimodality regimens have improved the survival
rates for AT/RT patients, AT/RT is still refractory to most treat-
ments (Fr€uhwald et al., 2016). Several preclinical studies at-
tempting to identify molecular targets of AT/RT have taken place
in recent years. Particularly, the inhibition of enhancer of zeste
homolog 2 (EZH2) has been reported to suppress rhabdoid
tumor cell growth, and a clinical trial with a specific inhibitor for
EZH2 has been in progress against SMARCB1-defective tumors
(Knutson et al., 2013; Alimova et al., 2013; Wilson et al., 2010).
Besides expectation of these preclinical studies, the develop-
ment of effective therapeutic approaches has been desired for
this deadly cancer.
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Figure 1. Generation of an Atypical Teratoid/Rhabdoid Tumor Model using hPSCs Lacking SMARCB1 and TP53
(A) A schematic illustration of the establishment of hiPSCs SMARCB1/; TP53/ and NPLCs SMARCB1/; TP53/.
(B) Representative morphology of hiPSCs, hiPSCs TP53/ and hiPSCs SMARCB1/; TP53/. Scale bars, 200 mm.
(C) The lack of TP53 and SMARCB1 proteins in hiPSCs SMARCB1/; TP53/ was confirmed by western blot analysis.
(D) Immunofluorescent staining for NESTIN in hiPSCs SMARCB1/; TP53/ and NPLCs SMARCB1/; TP53/. NESTIN-expressing cells emerged after neural
induction.
(E) A schematic illustration of the xenograft transplantation of hiPSCs or NPLCs into the brain of immunocompromised mice.
(F) MRI and representative histological images of a NPLC SMARCB1/; TP53/-derived tumor (NPLC-tumor). NPLCs SMARCB1/; TP53/ give rise to brain tumors,
which consist of densely packed undifferentiated small blue round cells with rosette formation. Scale bars, 500 mm (left) and 20 mm (right).
(legend continued on next page)
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Previous studies have shown that poorly differentiated tumors
in humans often exhibit activation of an embryonic stem cell
(ESC)-like gene expression signature, which is correlated with
a worse prognosis in adults (Ben-Porath et al., 2008; Wong
et al., 2008). Consistently, SALL4, one of the key factors in the
maintenance of pluripotency, is re-expressed in a subset of
hepatocellular carcinoma cells, especially in patients who have
an unfavorable prognosis, suggesting that the acquisition of
ESC-like features plays a role in cancer progression (Yong
et al., 2013). Takahashi and Yamanaka (2006) succeeded to
confer ESC properties to somatic cells upon the transient
expression of four reprogramming factors. Recently, an in vivo
reprogramming strategy, which enables the fate conversion of
differentiated somatic cells to pluripotent stem cells (PSCs)
in vivo, has been developed (Taguchi and Yamada, 2017).
Notably, a premature termination of the in vivo reprogramming
in mice causes the development of pediatric cancer-like tumors
with activation of the ESC-like signature (Ohnishi et al., 2014). In
addition, the transient expression of reprogramming factors in
Kras mutant mice causes the development of alfa-fetoprotein
(AFP)-producing cancers, which simultaneously express plurip-
otency-associated genes and exhibit activation of the ESC-like
signature (Shibata et al., 2018). Collectively, activation of the
ESC-like signature is involved in the development and progres-
sion of particular types of cancer.
Given that PSCs can give rise to various cell types while pre-
serving genetic information, human PSCs (hPSCs) have pro-
vided an attractive platform for disease modeling in a genetically
defined background in human cells. Indeed, previous studies
tried to model human cancers by using hPSCs (Kim et al.,
2013; Stricker et al., 2013; Sancho-Martinez et al., 2016), and
hESCs with genetic mutation at histone H3.3 succeeded to
model diffuse intrinsic pontine glioma in the proper cellular
context after neural differentiation (Funato et al., 2014). Here,
we established an AT/RT model using human induced
pluripotent stem cells (iPSCs) lacking SMARCB1. The human
iPSC-derived AT/RT model uncovered an unappreciated feature
of AT/RT, which could be a therapeutic target.
RESULTS
Generation of an Atypical Teratoid/Rhabdoid Tumor
Model using Human iPSCs Lacking SMARCB1 and TP53
A previous mouse study demonstrated that AT/RT-like tumors
develop when mutations for both Smarcb1 and p53 are intro-
duced into neural progenitor cells. In the present study, to
establish a human AT/RT model, we introduced genetic muta-
tions at SMARCB1 and TP53 into 201B7 human iPSCs
(hiPSCs) (hiPSCs SMARCB1/; TP53/) using the CRISPR/Cas9
system. We first established hiPSCs deficient of TP53 alone
(hiPSCs TP53/), and then introduced an additional mutation
at SMARCB1 to generate hiPSCs SMARCB1/; TP53/ (Figures
1A–1C). Subsequently, we induced neural differentiation in
hiPSCs SMARCB1/; TP53/, hiPSCs TP53/ and control 201B7
hiPSCs (Yan et al., 2013). iPSCs with all genotypes efficiently
changed their morphology into neural progenitor-like cells
(NPLCs) (Figure 1D). Consistently, NANOG and OCT4 expres-
sion were reduced in NPLCs at day 14 of the neural induction
(Figure S1A). In contrast, an increased expression of neural
progenitor cell (NPC)-related genes, such as NESTIN, NCAM,
and PAX6, was observed in these NPLCs (Figures S1A–S1C).
However, the expression levels of NPC-related geneswere lower
in NPLCs with SMARCB1 deficiency when compared with
wild-type control NPLCs (Figure S1A). Further induction of
neuronal differentiation in NPLCs confirmed that neuronal
differentiation is impaired in SMARCB1-deficient cells in vitro
(Figure S1B). We also examined the effect of SMARCB1 defi-
ciency on the cell growth of hPSCs and NPLCs in vitro. The
TP53 ablation promoted cell proliferation in both hPSCs and
NPLCs, whereas the SMARCB1 ablation inhibited the cell
growth of hiPSCs (Figure S1D). Although SMARCB1 deficiency
inhibited neuronal differentiation, it did not increase cell prolifer-
ation in NPLCs in vitro (Figure S1D).
To test the effect of SMARCB1 deficiency on the tumor-
forming ability of NPLCs in vivo, we performed xenograft trans-
plantation of NPLCs SMARCB1/; TP53/ and control NPLCs
into mouse brain (Figure 1E). The orthotopic transplantation of
NPLCs SMARCB1/; TP53/ caused the development of aggres-
sive tumors (n = 26/26) (Figures 1F and S1E). In contrast, control
201B7 NPLCs and NPLCs TP53/ gave rise to only microscopic
tumors (n = 2/2, 4/5, respectively) (Figures S1F and S1G), and no
macroscopic tumor was developed after the transplantation
(n = 0/4, 0/6, respectively) (Figure S1E). Together, SMARCB1
deficiency markedly promoted tumor formation from NPLCs
after orthotopic transplantation in vivo.
The histological analysis demonstrated that NPLC
SMARCB1/; TP53/-derived tumors (hereafter NPLC-derived
tumors) were medulloblastoma-like or embryonal tumor with
multilayered rosettes (ETMR)-like tumors, which mainly con-
sisted of densely packed undifferentiated small, blue, round
(G) Percentage of tumors with rhabdoid cells. hiPSC-tumors frequently contained rhabdoid cells, whereas a majority of NPLC-tumors did not. **p < 0.01
(Fisher’s exact test).
(H) Quantification of the rhabdoid area within a tumor. Note that the rhabdoid area is significantly larger in hiPSC-tumors than NPLC-tumors. Data are represented
as the median with interquartile range. **p < 0.01 (Mann-Whitney U test).
(I) MRI and representative histological images of a hiPSC SMARCB1/; TP53/-derived tumor (hiPSC-tumor). Note that the hiPSC-tumor contains a number of
rhabdoid cells. Scale bars, 500 mm (left) and 20 mm (right).
(J) Immunostaining for Ki67, SMARCB1, GFAP, vimentin, synaptophysin, S100, SMA, CD99, and EMA in a hiPSC-tumor. Tumor cells lack staining for SMARCB1.
The majority of hiPSC-tumor cells express Ki67, vimentin, and CD99, while a subset of tumor cells are positive for GFAP, synaptophysin, S100, SMA, and EMA.
Scale bars, 500 mm (top) and 50 mm (bottom). Areas in the high-magnification images are shown in the low-magnification images.
(K) Clustering analysis using all probes except for those of lowly expressed genes in a microarray analysis. Global expression profiles in tumors from SMARCB1-
defcient hiPSCs and NPLCs exhibited similar expression patterns with an AT/RT cell line. Note that medulloblastoma cell lines and a glioblastoma cell line are
independently clustered. Microarray data were obtained from GSE45265, GSE36947 (medulloblastomas), and GSE26313 (glioblastoma).
See also Figure S1.




Figure 2. hiPSC-Derived Tumors Exhibit Activation of the ESC-like Gene Expression Signature, which Drives Rhabdoid Tumors In Vivo
(A) Clustering analysis using microarray data revealed that both a hESC-like module genes (left) (Wong et al., 2008) and ESC Core module genes (right) (Kim et al.,
2010) are similarly expressed in an hiPSC-tumor, a NPLC-tumor, an AT/RT cell line, and hESC lines, whereas medulloblastoma lines and a glioblastoma cell line
are clustered with NSCs. The microarray data in Figure 1K were used. Data for NSCs were obtained from GSE18296 and GSE27667.
(B) Immunohistochemical analysis of SALL4, LIN28A, and LIN28B in hiPSC-tumors and NPLC-tumors. Scale bars, 50 mm.
(C) Quantification of the SALL4-positive cells in hiPSC-tumors and NPLC-tumors. Note that hiPSC-tumors contain SALL4-positive cells more frequently than
NPLC-tumors. Data are represented as the mean with 95% confidence interval. **p < 0.01 (unpaired t test with Welch’s correction).
(D) A qRT-PCR analysis for SALL4 and LIN28 expression in hiPSC- and NPLC-tumors. Data are presented as the mean of technical triplicates. The mean
expression level of hiPSC-tumors was set to 1. *p < 0.05 (unpaired t test with Welch’s correction).
(E) GSEA showing that the ESC-like module is enriched in hiPSC-tumors compared to NPLC-tumors.
(legend continued on next page)
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cells with rosettes (Figure 1F). However, the majority of
NPLC-derived tumors did not contain rhabdoid cells (Figures
1G and 1H), a characteristic histology of AT/RT. Although
NPCs have been suggested to be a cell-of-origin for
AT/RT, other studies proposed that pluripotent fetal cells,
which are more immature than NPCs, could be an origin
based on the morphology in an electron microscope analysis
and the unique gene expression in AT/RTs (Bouffard et al.,
2004; Deisch et al., 2011). Therefore, we next transplanted
hiPSCs SMARCB1/; TP53/ without neural induction (Fig-
ure 1E). The transplantation of hiPSCs SMARCB1/; TP53/ re-
sulted in aggressive tumor formation (n = 18/18) (Figures 1I
and S1E), which was similarly observed after the transplan-
tation of NPLCs SMARCB1/; TP53/. In contrast, the trans-
plantation of control 201B7 hiPSCs and hiPSCs TP53/
caused only microscopic tumor formation (n = 2/5 and 1/8,
respectively), and no macroscopic tumor formation was
observed after the transplantation (Figures S1E and S1F).
Notably, the histological analysis demonstrated that hiPSC
SMARCB1/; TP53/-derived tumors (hereafter hiPSC-derived
tumors) frequently contained a large number of rhabdoid
cells with vesicular chromatin, prominent nucleoli, and eosin-
ophilic globular cytoplasmic inclusions, which are represen-
tative histological features of AT/RT (Figures 1G and 1I).
The tumor area with rhabdoid histology was significantly
larger in hiPSC-derived tumors than NPLC-derived tumors
(Figure 1H). Immunohistochemical analyses revealed that
hiPSC-derived tumors exhibit shared features with AT/RT,
including high proliferative activity, lack of SMARCB1
expression, and positive staining for vimentin, glial fibrillary
acidic protein (GFAP), synaptophysin, CD99, S-100, EMA,
and smooth muscle actin (SMA) (Figure 1J). Consistent
with the histological observations, clustering analysis of
global gene expression revealed that a hiPSC-derived tumor
exhibited a similar expression pattern with an AT/RT cell line,
whereas medulloblastoma and glioblastoma cell lines fell into
a different cluster (Figure 1K). To exclude the possibility of a
PSC clone-specific phenotype, we also established an
SMARCB1-deficient PSC line by using a different iPSC line,
1383D6 (Figure S1H). The orthotopic transplantation of both
1383D6 iPSCs SMARCB1/ and 1383D6 NPLCs SMARCB1/
caused aggressive tumors (5/7 and 5/5, respectively) (Fig-
ure S1I), which phenocopied the tumors from 201B7 iPSCs
and NPLCs lacking SMARCB1 and TP53. Notably, four out
of five 1383D6 iPSC SMARCB1/-derived tumors contained
rhabdoid cells, although the area of the rhabdoid cells was
smaller than in 201B7 hiPSC SMARCB1/; TP53/-derived tu-
mors (Figures S1I and S1J). In sharp contrast, no rhabdoid
cells were detected in 1383D6 NPLC SMARCB1/-derived tu-
mors (Figures S1I and S1J). Collectively, we succeeded to
model human AT/RT by inoculation of hiPSCs lacking
SMARCB1 into mouse brain.
hiPSC-Derived Tumors Exhibit an ESC-like Gene
Expression Signature
Our results demonstrating that iPSC-derived tumors exhibited a
robust rhabdoid phenotype raised the possibility that a pluripo-
tency-related program is associated with the characteristic rhab-
doid histology. Therefore, we next investigated the expression of
ESC-related modules in hiPSC- and NPLC-derived tumors
together with various brain tumor cell lines. Notably, both hiPSC-
and NPLC-derived tumors together with an AT/RT cell line ex-
hibited the ESC-like activation patterns of ESC-related modules,
including the ESC Core module, which is composed of genes
co-occupied by multiple factors in the core pluripotency network
(Figure 2A) (Kim et al., 2010;Wong et al., 2008).We next analyzed
the expression of SALL4, LIN28A, and LIN28B, which are associ-
ated with the maintenance and acquisition of pluripotency, in
hiPSC- and NPLC-derived tumors. Immunohistochemical anal-
ysis revealed that both hiPSC- and NPLC-derived tumors ex-
pressed SALL4, LIN28A, and LIN28B, but the expression was
particularly pronounced in hiPSC-derived tumors (Figures 2B
and 2C). We also confirmed the elevated expression of SALL4
and LIN28B in hiPSC-derived tumors by qRT-PCR (Figure 2D).
Consistently, gene set enrichment analysis (GSEA) showed an
enrichment of the ESC-like module (Wong et al., 2008) in
hiPSC-derived tumors compared to NPLC-derived tumors (Fig-
ure 2E) (Subramanian et al., 2005). Together, we confirmed the
ESC-like signature is activated in hiPSC-derived tumors.
Induction of the ESC-like Signature Leads to Rhabdoid
Phenotypes in NPLC-Derived Tumors
To further investigate the role of the pluripotency-related signa-
ture in the histogenesis of rhabdoid cells, we next tried to
induce the ESC-like signature during tumor development
from NPLCs SMARCB1/; TP53/ by the forced expression of
four reprogramming factors, namely, OCT4, SOX2, KLF4, and
c-MYC (OSKM-NPLCs) (Figure S2A). It was reported that
the removal of polysialylated-neural cell adhesion molecule
(PSA-NCAM)-negative cells could prevent mesodermal tumor
formation in hiPSC-derived NPC transplantation, indicating
that PSA-NCAM antibody is useful for excluding undifferenti-
ated, tumor-forming PSCs after neural induction (Lee et al.,
2015). To eliminate the tumorigenic undifferentiated PSCs after
neural induction into NPLCs SMARCB1/; TP53/, we sorted
neural-differentiated cells with the PSA-NCAM antibody using
(F) A schematic illustration of the xenograft transplantation study. PSA-NCAM-positive NPLCs SMARCB1/; TP53/ were sorted by MACS, followed by the
retroviral transduction of GFP (GFP-NPLCs) or OSKM (OCT4, SOX2, KLF4, and c-MYC: OSKM-NPLCs) and orthotopic transplantation into the mouse brain.
(G) GSEA showing that the ESC-like module is activated in OSKM-NPLC-tumors compared to control NPLC-tumors.
(H) Representative histological images of an OSKM-NPLC-tumor. A number of rhabdoid cells are observed in the tumor. Scale bars, 500 mm (top) and 20 mm
(bottom).
(I) Quantification of the rhabdoid area in OSKM-NPLC-tumors. Note that the rhabdoid areas in OSKM-NPLC-tumors are significantly larger than those in the
control NPLC-tumors. Data are represented as the mean with 95% confidence interval. ****p < 0.0001 (unpaired t test with Welch’s correction).
(J) Survival curve ofmice transplantedwith hiPSCs SMARCB1/; TP53/ or NPLCs SMARCB1/; TP53/. The overall survival of hiPSC SMARCB1/; TP53/-transplanted
mice is shorter than NPLC SMARCB1/; TP53/-transplanted mice. Kaplan-Meier analysis was performed. *p < 0.05 (log-rank test).
See also Figure S2.
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magnetic-activated cell sorting (MACS). We confirmed the high
efficiency of MACS of PSA-NCAM-positive cells by a flow cyto-
metric analysis (Figure S2B). OCT4, SOX2, KLF4, and c-MYC
were retrovirally transduced into NPLCs or PSA-NCAM-positive
NPLCs (Figure S2C), and theOSKM-NPLCswere inoculated into
the mouse brain to obtain NPLC-derived tumors (Figures 2F and
S2A). All mice transplanted with OSKM-NPLCs developed
aggressive brain tumors (n = 9). Although OSKM-NPLCs did
not exhibit a prominent upregulation of pluripotency-related
genes in vitro (Figure S2D), an enrichment of the ESC-like mod-
ule was observed in OSKM-NPLC-derived tumors when
compared to control NPLC-derived tumors (Figure 2G), suggest-
ing thatOSKM induction conferred the ESC-like gene expression
signature in NPLC-derived tumors (Wong et al., 2008). Of partic-
ular note, OSKM-NPLC-derived tumors exhibited an apparent
rhabdoid histology in most areas (Figure 2H). Consistently, the
rhabdoid area in OSKM-NPLC-derived tumors was significantly
larger than that in control NPLC-derived tumors (Figure 2I).
Collectively, we concluded that activation of the ESC-like signa-
ture is responsible for the characteristic rhabdoid histology.
Orthotopic Transplantation of hiPSCs SMARCB1/; TP53/
Results in Poor Survival Compared to
NPLC SMARCB1/; TP53/ Transplantation
Previous studies demonstrated that activation of the ESC-like
signature in tumors is associated with a worse prognosis of
adult cancer patients (Ben-Porath et al., 2008). Therefore,
we next investigated the survival period of mice after the
orthotopic transplantation of hiPSCs SMARCB1/; TP53/ and
NPLCs SMARCB1/; TP53/. Consistent with a positive correlation
between activation of the ESC-like signature and the poor prog-
nosis, the overall survival of hiPSC SMARCB1/; TP53/-trans-
planted mice that developed tumors with rhabdoid histology
was substantially shorter than NPLC
SMARCB1/; TP53/-trans-
planted mice (Figure 2J). Similarly, mice inoculated with OSKM-
NPLCs, which also developed tumors with rhabdoid histology,
exhibited poor survival when compared to mice inoculated with
control NPLCs (Figures S2E and S2F). Together, these results
indicate that activation of the ESC-like signature is associated
with a worse prognosis of SMARCB1-defecient tumors.
c-MYC Induces Activation of the ESC-like Signature in
NPLC-Derived Tumors and Drives Rhabdoid Tumor
Development In Vivo
Our results indicate that activation of the ESC-like signature is
associated with the unique rhabdoid histology and poor prog-
nosis of AT/RT. However, how AT/RT cells acquire the ESC-
like signature remains unclear. A previous study demonstrated
that c-Myc activates the ESC-like signature in adult epithelial
cells and cancer cells and increases the fraction of tumor-
initiating cells (Wong et al., 2008). Considering that c-MYC is
overexpressed in a subset of AT/RTs (Johann et al., 2016), we
next investigated the effect of c-MYC induction on the
activation of the ESC-like signature and the rhabdoid pheno-
type in NPLC-derived tumors. c-MYC was retrovirally trans-
duced in NPLCs SMARCB1/; TP53/ or PSA-NCAM-positive
NPLCs SMARCB1/; TP53/ (MYC-NPLCs), and then MYC-
NPLCs were inoculated into mouse brain (Figures 3A, S3A,
and S3B). Notably,MYC-NPLCs gave rise to aggressive tumors
containing a large number of rhabdoid cells (Figures 3B, 3C, S3C
and S3D). Moreover, these tumors exhibited an activation of
ESC-like module genes (Figure 3D) and increased expression
of SALL4 and LIN28 (Figure 3E) compared to control tumors.
To investigate the effect of c-MYC overexpression on the dis-
ease outcome, we next investigated the survival period of mice
transplanted with MYC-NPLCs. The overall survival of these
mice was significantly shorter than that of controls (Figures 3F
and S3E). Collectively, these results demonstrate that c-MYC
overexpression alone is sufficient for activation of the ESC-like
signature and rhabdoid histology in NPLC-derived tumors,
which was linked to a worse prognosis.
Activation of the ESC-like Gene Expression Signature in
Human AT/RT Specimens
Above, we showed that activation of the ESC-like signature
is related to the emergence of rhabdoid cells, a unique histo-
logical feature of AT/RT, and the worse prognosis of
NPLC SMARCB1/; TP53/-transplanted mice. We next exam-
ined the gene expression profile of clinical samples of human
AT/RTs, medulloblastomas, and glioblastomas by using previ-
ously published datasets. Clustering analysis revealed that
ESC-like module genes (Wong et al., 2008) are similarly acti-
vated in AT/RT samples and ESCs and iPSCs, whereas me-
dulloblastomas and glioblastomas fall into a different cluster
(Figure 4A). Similar results were obtained in the clustering
analysis using the ESC Core module (Figure 4A) (Kim et al.,
2010). We also examined activation of the ESC-like signature
in ETMRs, which often show LIN28A immunoreactivity.
Notably, some ETMRs also exhibited ESC-like activation of
the ESC Core module genes (Figure S4A). Consistent with
the ESC-like gene expression signature, the expression of
SALL4, LIN28A, and LIN28B were elevated in AT/RTs
compared to glioblastomas (Figure 4B). SALL4 was highly ex-
pressed in AT/RTs compared with medulloblastomas, but the
expression level of LIN28B was higher in medulloblastomas
(Figure 4B). The increased expression of SALL4, LIN28A,
and LIN28B were also confirmed in AT/RT clinical specimens
by immunohistochemistry (Figure S4B) (Deisch et al., 2011)
(Weingart et al., 2015). Taken together, we confirmed that
human AT/RTs harbor the ESC-like signature.
ESC-like DNA Methylation Landscape in Human AT/RT
Specimens
Given that human AT/RTs exhibit the ESC-like gene expression
signature, we next examined DNAmethylation patterns between
AT/RTs and PSCs. We performed a comprehensive genome-
wide methylation analysis of CpG islands (CGIs) in AT/RTs
together with other brain tumors by using previously published
datasets. In this analysis, we first extracted CpG sites within
CGIs or around transcription start sites (TSSs; ± 1,500 bp), which
are differentially methylated between PSCs and adult brain tis-
sues (DNAme difference [Dif], >0.6), and then examined DNA
methylation levels in AT/RTs, medulloblastomas, ETMRs, glio-
blastomas, fetal brain tissues, and neural stem cells (NSCs).
We found that CGI methylation levels at brain-unmethylated
sites (PSC-methylated sites) are often increased in AT/RTs but
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not so much in other tumors or NSCs (Figures 4C and S5).
Although ETMRs exhibited the ESC-like gene expression signa-
ture, PSC-methylated sites remain unmethylated in ETMRs (Fig-
ure S5). In contrast, CGI methylation levels at adult brain-
specifically methylated sites tended to be decreased in AT/RTs




Figure 3. c-MYC Induces Activation of the ESC-like Signature and Drives Rhabdoid Tumors In Vivo
(A) A schematic illustration of the xenograft transplantation study. PSA-NCAM-positive NPLCs SMARCB1/; TP53/ were sorted by MACS and then retrovirally
transduced with GFP (GFP-NPLC) or c-MYC (MYC-NPLC), which were transplanted into the mouse brain. The control NPLCs are the same as Figure 2F.
(B) Representative histological images of GFP-NPLC-tumors andMYC-NPLC-tumors.MYC-NPLC-tumors contain rhabdoid cells. Scale bars, 500 mm (top) and
20 mm (bottom).
(C) Quantification of the rhabdoid area in NPLC-tumors. Note that the rhabdoid area in MYC-NPLC-tumors is significantly larger than in control NPLC-tumors.
Data are represented as the mean with 95% confidence interval. ****p < 0.0001 (unpaired t test with Welch’s correction).
(D) GSEA showing that the ESC-like module is enriched in MYC-NPLC-tumors compared to control NPLC-tumors.
(E) Expression levels of LIN28B and SALL4 inMYC-NPLC-tumors, control NPLC-tumors, iPSCs, and human dermal fibroblasts (HDF) by RNA sequencing (RNA-
seq) analysis. Lines indicate mean expression values. RPKM, reads per kilobase of exon per million mapped sequence reads.
(F) Survival curves of mice transplanted withMYC-NPLCs or control NPLCs. The overall survival of mice inoculated withMYC-NPLCs is significantly shorter than
of controls. Kaplan-Meier analysis was performed. ****p < 0.0001 (log-rank test).
See also Figure S3.
2614 Cell Reports 26, 2608–2621, March 5, 2019
A C
B
Figure 4. Human AT/RT Specimens Exhibit Activation of the ESC-like Gene Expression Signature and ESC-like DNAMethylation Landscape
(A) Clustering analysis usingmicroarray data revealed that both hESC-likemodule genes (left) and ESCCoremodule genes (right) are similarly expressed in AT/RT
samples and ESCs and iPSCs. Note that medulloblastoma (MB) and glioblastoma (GBM) samples are clustered separately from ESCs and iPSCs. Microarray
data of hPSCs, AT/RTs, medulloblastomas, and glioblastomas were obtained from GSE22392 (hESC/hiPSC), GSE70678 (AT/RT), GSE37418 (MB), and
GSE53733 (GBM).
(B) Expressions of SALL4 and LIN28 in AT/RTs, medulloblastomas, and glioblastomas compared to ESCs and iPSCs. Data are represented as the median with
interquartile range. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (Kruskal-Wallis test and Dunn’s multiple comparisons test). The same microarray data as
Figure 4A were used.
(C) The DNAmethylation landscape in AT/RTs analyzed using Infinium450K data. In this analysis, we first extracted differentially methylated CpG sites within CpG
islands (CGIs) between hPSCs and adult brains. hPSC-specific methylated CpG sites and adult brain-specific methylated CpG sites within CGIs were analyzed
(legend continued on next page)
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brain tissues or NSCs (Figures 4C and S5). Similar patterns of
DNA methylation alterations were observed at CpG sites around
TSSs (Figure S5). Taken together, we concluded that AT/RTs
harbor an ESC-like DNA methylation landscape.
Pediatric Cancers Exhibit Activation of the ESC-like
Gene Expression Signature
Previous studies demonstrated that pluripotency-related genes,
such as LIN28B, are frequently upregulated in other pediatric
cancers that occur in early childhood, which raised the possibil-
ity that activation of the ESC-like signature is a shared feature in
pediatric cancers. Therefore, we next examined the expression
of the ESC-like module genes in three other pediatric cancers,
namely, neuroblastoma (NB), Wilms’ tumor (WT), and hepato-
blastoma (HB), by comparing them with their corresponding
adult cancer, namely, adrenocortical carcinoma (ACC), renal
cell carcinoma (RCC), and hepatocellular carcinoma (HCC),
respectively. Notably, a principal-component analysis (PCA) re-
vealed that all three pediatric cancer types exhibited similar
expression profiles with PSCs and activation of the ESC-like
module genes compared to the corresponding adult cancers
(Figures 5A and S6). Consistently, the pediatric cancers showed
increased expression of SALL4 and LIN28B compared to their
counterparts (Figure 5B). Together, our data indicate that activa-
tion of the ESC-like signature is a common characteristic of
pediatric cancers.
Genetic Screening with CRISPR/Cas9 to Develop a
Strategy for AT/RT Therapy
Our findings about activation of the ESC-like signature suggest
the signature could make a promising therapeutic target for
AT/RT. Therefore, we performed genetic screening to identify
genes that play a role in the malignant features of AT/RT (Fig-
ure 6A). Accordingly, we picked out 110 target genes that are
associated with the maintenance of ESC identity based on
previous reports (Tables S1 and S2). A lentiviral CRISPR/Cas9
system was employed to disrupt the candidate genes in a
cancer cell line, which was established from hiPSC-derived tu-
mors (Figure 6A; Table S1). The high efficiency of non-homolo-
gous end joining by this lentiviral CRISPR/Cas9 system was
confirmed 7 days after lentiviral transduction in the pediatric
cancer cell line SK-N-BE(2) (Figure S7A). The genetic screening
revealed decreased cancer cell growth after the transduction of
CRISPR/Cas9 together with single guide RNA (sgRNA) for
dozens of genes compared to non-targeting control (NTC)
sgRNA (Figure 6B; Table S3). Notably, among the candidate
genes was Enhancer of zeste homolog 2 (EZH2), which has
been reported as a target of AT/RT treatment (Knutson et al.,
2013; Alimova et al., 2013; Wilson et al., 2010), indicating
that our screening successfully identified potential therapeutic
targets. Indeed, we confirmed that GSK126, a specific inhibitor
for EZH2, efficiently suppressed growth of the hiPSC-derived
cancer cell line. Moreover, GSK126 efficiently inhibited the
ESC-like signature in the hiPSC-derived cancer cell line
(Figure S7B).
Given that other pediatric cancers similarly exhibit activation
of the ESC-like signature, we also performed the same genetic
screening in two neuroblastoma cell lines, namely, SK-N-AS
and SK-N-BE(2). We found that RAD21 knock out efficiently
reduced cell proliferation in the hiPSC-derived cancer cell line
and neuroblastoma cell lines (Figures 6B and 6C). The inhibitory
effect of cell growth was confirmed in another guide RNA target-
ing RAD21 (Figure S7C). Notably, RAD21 as well as EZH2 was
highly expressed in AT/RTs compared to glioblastomas (Fig-
ure 6D). Moreover, the increased expression of RAD21 and
EZH2 was similarly observed in other pediatric cancers,
including neuroblastomas, Wilms’ tumors, and hepatoblasto-
mas, when compared to the corresponding adult cancers
(Figure 6E). Therefore, we focused on RAD21 and EZH2 and
conducted further experiments.
The inhibitory effect on tumor cell growth in the hiPSC-derived
cancer cell line by the knockout of RAD21 and EZH2 was vali-
dated in a large-scale culture (Figure 6F). Xenograft experiments
revealed that the lentiviral CRISPR/Cas9-mediated knock out of
RAD21 or EZH2 extended the overall survival of mice after the
inoculation of hiPSC-derived cancer cells (Figures 6G and 6H).
Therefore, we concluded that RAD21 and EZH2 are potential
therapeutic targets for AT/RTs.
RAD21 is a key central component within the multi-protein
cohesin complex. A previous study demonstrated that histone
deacetylase 8 (HDAC8) functions as a deacetylase of SMC3,
another component of the cohesin complex, and plays a role in
recycling cohesin during cell division (Deardorff et al., 2012).
Moreover, it was shown that PCI34051, a HDAC8-specific inhib-
itor, reduces the localized cohesin, indicating that the inhibitor
impairs cohesin function. Considering that RAD21 knock out in-
hibited cancer cell growth in the AT/RT model, we next investi-
gated the effect of PCI34051 on cancer cell growth in this model.
PCI34051 treatment resulted in a modest reduction in the cell
growth of hiPSC-derived cancer cells (Figures 6I and S7D). The
growth inhibitory effect was not obvious in the presence of
siRAD21, which supports the notion that PCI34051 inhibits cell
growth by impairing cohesin function (Figure S7D). Most notably,
simultaneous treatment with PCI34051 and GSK126 markedly
inhibited the cell proliferation (Figure 6I). Mechanistically, sup-
pression of the ESC-like gene expression signature by GSK126
was more pronounced by the combination treatment of
PCI34051 and GSK126 (Figures 6J and S7E), although
PCI34051 alone did not significantly suppress the ESC-like
signature (Figure S7F). Consistently, a gene ontology enrichment
analysis revealed that the combination treatment induced genes
associated with nervous system development (Figure 6K), sug-
gesting that the combined inhibition of HDAC8 and EZH2
induced neuronal differentiation. We also confirmed that the
for AT/RTs and medulloblastomas as well as fetal brains and NSCs. AT/RTs harbor increased methylation at the PSC-specific methylated CpG sites, whereas
adult brain-specific methylated CpG sites are less methylated in AT/RTs. Each dot indicates the median of DNA methylation at the analyzed CpG sites.
Infinium450K data of hPSCs, normal brains, fetal brains, NSCs, AT/RTs, andmedulloblastomas were obtained fromGSE60821 (hPSC), GSE92462 (hPSC, normal
brain, fetal brain, and NSC), GSE36278 (normal brain and fetal brain), GSE70460 (AT/RT), and GSE75153 (MB).
See also Figures S4 and S5.
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combination treatment remarkably suppressed proliferation in
other rhabdoid and AT/RT cell lines (Figure 6L), as well as neuro-
blastoma cell lines (Figure 6M). In sharp contrast, the suppres-
sive effect was not prominent in two of three glioblastoma cell
lines (Figure S7G), which is consistent with the fact that most
glioblastomas do not exhibit activation of the ESC-like signature.
DISCUSSION
In the present study, we established hPSCs deficient for
SMARCB1 to model AT/RT. Although previous studies sug-
gested that NPCs are a cell-of-origin for AT/RT, the majority of
tumors from SMARCB1-deficient NPLCs lacked typical rhab-
doid cells. On the other hand, despite having the same genetic
abnormality, the transplantation of SMARCB1-deficient hPSCs
caused tumors containing a large number of rhabdoid cells, indi-
cating that PSC-related embryonic cell properties are associ-
ated with the histogenesis of rhabdoid cells, which was
further supported by the fact that forced activation of the ESC-
like signature confers the rhabdoid histology in SMARCB1-
deficient NPLC-derived tumors. Consistent with that notion,
we found activation of the ESC-like signature in clinical speci-
A
B
Figure 5. Pediatric Cancers Exhibit Activa-
tion of the ESC-like Gene Expression
Signature
(A) Principal-component analysis of gene expres-
sions in pediatric cancers and adult cancers using
hESC-like module genes (top) and ESC Core
module genes (bottom). Note that all pediatric
cancers exhibit activation of the ESC-like module
and the ESC Core module when compared to the
corresponding adult cancers. AT/RT, atypical
teratoid/rhabdoid tumor; NB, neuroblastoma; WT,
Wilms’ tumor; HB, hepatoblastoma; GBM, glio-
blastoma; ACC, adrenocortical carcinoma; RCC,
renal cell carcinoma; HCC, hepatocellular carci-
noma. Microarray data of hPSCs and pediatric
and adult cancers were obtained from GEO:
GSE22392 (hESC/hiPSC), GSE70678 (AT/RT),
GSE16476 (neuroblastoma), GSE11151 (Wilms’
tumor/renal cell carcinoma), GSE53224 (Wilms’
tumor), GSE75271 (hepatoblastoma), GSE53733
(GBM), GSE10927 (adrenocortical carcinoma),
GSE66272 (renal cell carcinoma), and GSE62232
(hepatocellular carcinoma).
(B) Expressions of SALL4 and LIN28B in pediatric
cancers and adult cancers. Note that pediatric
cancers show increased expression of SALL4 and
LIN28B compared to the corresponding adult
cancers. Data are represented as the median with
interquartile range. ****p < 0.0001 (Mann-Whitney
U test). The same microarray data as Figure 5A
were used.
See also Figure S6.
mens of AT/RTs but not in medulloblas-
tomas or glioblastomas. Of particular
note, SMARCB1-deficient hPSC-trans-
planted mice showed poor survival
compared to SMARCB1-deficient NPLC-
transplanted mice, indicating a positive correlation between acti-
vation of the ESC-like signature and poor prognosis. Collectively,
we developed a human AT/RT model using hPSCs and identified
activation of the ESC-like signature as an important determinant
of the unique histology and poor prognosis of AT/RT.
The fact that rhabdoid histology is prominent in PSC-derived
tumors compared to NPLC-derived tumors suggests that an
earlier embryonic program than the NPC program is involved in
the unique histology. However, it remains unclear how AT/RT
cells acquire the ESC-like signature in the postnatal brain.
Notably, we found that ESC-methylated CpG sites are unmethy-
lated in NSCs and fetal brains, suggesting that the ESC-like
methylation patterns in AT/RTs do not simply reflect the DNA
methylation patterns in NSCs or fetal cells. These findings may
support the assumption that the ESC-like signature is acquired
during AT/RT development. It is also interesting to note that ge-
netic ablation of TP53 seems to enhance the emergence of
the rhabdoid histology, although clinical AT/RTs hardly harbor
the TP53mutation. Given that the loss of TP53 greatly promotes
somatic cell reprogramming into iPSCs (Hong et al., 2009), it is
possible that TP53 deficiency contributed to the acquisition of
the ESC-like signature by accelerating the reprogramming
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process in this particular model. In contrast, we found that TP53
deficiency alone did not promote the tumor formation in vivo,
suggesting that the TP53 deficiency enhances tumor formation
in conjunction with SMARCB1 deficiency.
Notably, we showed that c-MYC overexpression induces
activation of the ESC-like signature in NPLC-derived tumors
and drives tumor development with the rhabdoid phenotype.
A previous study demonstrated that c-MYC activates the
embryonic transcriptional programand causes stemcell-like phe-
notypes (Wong et al., 2008). Moreover, a recent study demon-
strated that c-MYC-driven dedifferentiation supports the onset
of a stem cell-like state and tumorigenesis in mammary epithelial
cells (Poli et al., 2018). Together, we propose that c-MYC induces
dedifferentiation and activates the ESC-like signature during
tumor development from SMARCB1-deficient NPLCs. The fact
that c-MYC is frequently amplified in AT/RT in patients at higher
age (Johann et al., 2016) may further support the notion that
c-MYC induces dedifferentiation during AT/RT development.
Taking advantage of our human AT/RTmodel, we showed that
activation of the ESC-like signature is correlated with the poor
prognosis, which raised the possibility that the ESC-like signa-
ture is a promising therapeutic target for AT/RT. Accordingly,
we performed a CRISPR/Cas9 knock out screening targeting
themaintenance of ESC identity and identified genes that poten-
tially maintain the growth of tumor cells. Notably, the identified
genes included EZH2, which was previously reported as a
potential therapeutic target in AT/RT (Choi et al., 2016; Weingart
et al., 2015). Importantly, we found that an EZH2 inhibitor effi-
ciently inhibited the ESC-like signature in AT/RT cells, which is
consistent with a previous study that demonstrated Ezh2 main-
tains the stem cell-associated signature in Smarcb1-deficient
mouse embryonic fibroblasts (Wilson et al., 2010).
We also found that knock out of RAD21, which encodes a
component within the cohesin complex, significantly suppresses
the growth of AT/RT cells, suggesting that the function of
cohesin too could be a target for AT/RT treatment. Consistently,
an HDAC8-specific inhibitor, which indirectly reduces localized
cohesin, together with the EZH2 inhibitor synergistically inhibited
activation of the ESC-like signature andmarkedly suppressed the
proliferation of AT/RT cells but hadminimal effect on glioblastoma
cells. Although a mechanistic basis for the potent inhibition of the
ESC-like signature by the combined inhibition of EZH2 and
HDAC8 remains to be solved, we propose that inhibition of the
ESC-like signature is an effective strategy for AT/RT treatment.
It is interesting that activation of the ESC-like signature was
similarly detectable in other pediatric cancers, such as neuro-
blastomas, Wilms’ tumors, and hepatoblastomas. Notably, the
same knock out screening in neuroblastoma cell lines revealed
that knock out of RAD21 often suppressed the growth of neuro-
blastoma cells. Furthermore, the combined treatment with EZH2
and HDAC8 inhibitors synergistically reduced the proliferation of
neuroblastoma cells. Together with previous findings that partial
reprogramming in vivo induces activation of the ESC-like signa-
ture and causes the development of cancers that resemble
pediatric cancers (Ohnishi et al., 2014), it is possible that activa-
tion of the ESC-like signature may be a general driver of pediatric
Figure 6. CRISPR/Cas9-Mediated Genetic Screening to Develop a Therapeutic Strategy for AT/RT
(A) A schematic illustration of the genetic screening with the lentiviral CRISPR/Cas9 system. An alamarBlue assay was performed to evaluate cell viability. The
LentiCRISPR-transduced cell population was examined at days 3–5 and then used for the adjustment to determine the cell growth ratio at day 9. The average of
the duplicate values was used for each assay.
(B) The results of a genetic screening of the hiPSC SMARCB1/; TP53/-derived cancer cell line. The transduction of CRISPR/Cas9with sgRNA targeting EZH2 and
RAD21 inhibited cell growth.
(C) The results of a genetic screening of the neuroblastoma cell lines SK-N-AS and SK-N-BE(2). The LentiCRISPR-transduced cell population was examined at
days 3 and 4, then used for the adjustment to determine the cell growth ratio at days 7–12. The transduction of CRISPR/Cas9 with sgRNA forRAD21 inhibited cell
proliferation in both cell lines.
(D) The expression of EZH2 andRAD21 in AT/RTs and glioblastomas. The increased expressions of both EZH2 andRAD21were observed in AT/RTs compared to
glioblastomas. The same microarray data as Figure 4A were used. ****p < 0.0001 (Kruskal-Wallis test and Dunn’s multiple comparisons test).
(E) The expression of EZH2 and RAD21 in pediatric cancers and the corresponding adult cancers. Note that the increased expressions of RAD21 and EZH2were
similarly observed in other pediatric cancers. Data are represented as the median with interquartile range. ***p < 0.001, ****p < 0.0001 (Mann-Whitney U test). The
same microarray data as Figure 5A were used.
(F) Growth ratios (day 11/day 3) of hiPSC-derived cancer cells transduced with CRISPR/Cas9 with sgRNA for non-targeting control (NTC), EZH2, or RAD21. The
transduction of CRISPR/Cas9 with sgRNA for EZH2 and RAD21 reduced the cell growth ratio compared to NTC. Data are presented as the mean of three
biological replicates with standard deviation. The growth ratio of NTC-transduced cells was set to 1. *p < 0.05, ****p < 0.0001 (Kruskal-Wallis test and Dunn’s
multiple comparisons test).
(G) A schematic illustration of the xenograft transplantation study of hiPSC-derived cancer cells transduced with lentiCRISPR/Cas9 together with sgRNA forNTC,
EZH2, or RAD21.
(H) Survival curves of mice transplanted with hiPSC-derived cancer cells transduced with CRISPR/Cas9 and sgRNA for NTC, EZH2, or RAD21. Kaplan-Meier
analysis was performed. *p < 0.05, **p < 0.01 (log-rank test).
(I) Cell viability of hiPSC-derived cancer cells treatedwithDMSO,PCI34051 (10mM),GSK126 (10mM), or a combination of PCI34051 andGSK126 (10mMeach). Note
that the inhibitory effect is markedly enhanced by the combination treatment. **p < 0.01, ***p < 0.001 (one-way ANOVA and Dunnett’s multiple comparisons test).
(J) GSEA showing the suppression of the ESC-like module by the combined treatment of PCI34051 and GSK126 compared to DMSO treatment in hiPSC-derived
cancer cells.
(K) Gene ontology enrichment analysis showing that the combined treatment of PCI34051 and GSK126 resulted in the induction of genes associated with
neuronal development in hiPSC-derived cancer cells. Genes showingR1.5-fold changes compared to DMSO-treated cells were used in the analysis.
(L) Cell viability of rhabdoid cell lines treated with DMSO, PCI34051 (10 mM), GSK126 (10 mM), or the combination of PCI34051 and GSK126 (10 mM each).
*p < 0.05, ***p < 0.001, ****p < 0.0001 (one-way ANOVA and Dunnett’s multiple comparisons test).
(M) Cell viability of neuroblastoma cell lines treated with DMSO, PCI34051 (10 mM), GSK126 (10 mM), or the combination of PCI34051 and GSK126 (10 mM each).
***p < 0.001, ****p < 0.0001 (one-way ANOVA and Dunnett’s multiple comparisons test).
See also Figure S7 and Table S1.
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cancer development and, therefore, could be a therapeutic
target for pediatric cancers. Indeed, previous studies showed
that EZH2 inhibitors are often effective for pediatric cancers
(Chen et al., 2018) and that an HDAC8 inhibitor suppresses cell
proliferation and induces differentiation in neuroblastoma cells
(Oehme et al., 2009). Collectively, we propose that the combined
inhibition of EZH2 and HDAC8 could be a promising strategy to
treat pediatric cancers by targeting the ESC-like signature.
In summary, we established a human AT/RT model using
SMARCB1-deficient hPSCs. Taking advantage of the AT/RT
model, we unveiled that activation of the ESC-like signature
plays a central role in the unique rhabdoid histology and poor
prognosis of AT/RT. Finally, we showed that this signature could
be a promising therapeutic target for AT/RT as well as other
pediatric cancers.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti-SALL4 Abnova Cat# clone 6E3; RRID: AB_566160
Anti-LIN28A Cell Signaling Technology Cat# 8706; RRID: AB_10896850
Anti-LIN28B Cell Signaling Technology Cat# 5422; RRID: AB_10697489
Anti-Ki67 (SP6) Abcam Cat# ab16667; RRID: AB_302459
Anti-INI1/SNF5 Sigma-Aldrich Cat# SAB4200202; RRID: AB_10697389
Anti-Vimentin (V9) SantaCruz Cat# sc-6260; RRID: AB_628437
Anti-GFAP DAKO Cat# IR524
Anti-CD99 DAKO Cat# clone 12E7; RRID: AB_2076419
Anti-S100 DAKO Cat# GA504
Anti-EMA Novocastra Cat# NCL-L-EMA; RRID: AB_563531
Anti-SMA Nichirei Cat# clone1A4
Anti-Synaptophysin Nichirei Cat# clone27G12
Anti-NESTIN Millopore Cat# MAB5326; RRID: AB_2251134
Anti-TP53 Santa Cruz Cat# sc-126; RRID: AB_628082
Anti-b-actin Santa Cruz Cat# sc-47778; RRID: AB_626632
ECL anti-mouse IgG, HRP-linked whole
antibody from sheep
GE Healthcare Cat# NA931; RRID: AB_772210
ESC anti-rabbit IgG and HRP-linked
whole antibody from donkey
GE Healthcare Cat# NA934; RRID: AB_772206
Anti-PSA-NCAM antibody conjugated
with microbeads
Miltenyi Biotec Cat# 130-92-981
Anti-PSA-NCAM Millipore Cat# MAB5324; RRID: AB_95211
StemFit AK03N Ajinomoto Cat# AK03N
StemFit AK02N Ajinomoto Cat# AK02N
Laminin-511 Wako Cat# 892012
PSC Neural Induction Medium Life Technologies Cat# A1647801
Y27632 Wako Cat# 253-00513
Chemicals, Peptides, and Recombinant Proteins
GSK126 Funakoshi Cat# A-1275
PCI34051 Selleck Cat# S2012
siGENOME SMARTpool siRNA, RAD21 Dharmacon Cat# M-006832-01-0005
siGENOME SMARTpool siRNA, Non-Targeting Dharmacon Cat# D-001206-13-05
Critical Commercial Assays
AlamarBlue cell viability reagent Bio-Rad Cat# BOF012B
Cell Counting Kit-8 Dojindo Cat# 341-07761
Human Gene 1.0 ST Array Affymetrix Cat# 901086
Truseq Stranded mRNA LT sample prep kit Illumina Cat# RS-122-2101, RS-122-2102
Deposited Data
Microarray data This paper GSE118653
RNA-seq data This paper GSE118654
Affymetrix Human Gene 1.0ST Array datasets Gene Expression Omnibus GEO: GSE26313, GSE45265, GSE36947,
GSE18296 and GSE27667
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Affymetrix Human Genome U133 Plus 2.0
Array datasets
Gene Expression Omnibus GEO: GSE70678, GSE37418, GSE53733,
GSE16476, GSE11151, GSE53224,




Gene Expression Omnibus GEO: GSE60821, GSE92462, GSE70460,
GSE75153, GSE36278 and GSE73801
Experimental Models: Cell Lines
Human: 201B7 hiPSC Laboratory of Masato Nakagawa hiPS Cell Line: 201B7
Human: 1383D6 hiPSC Laboratory of Masato Nakagawa hiPS Cell Line: 1383D6
Human: KUP-ATRT-1 Kyoto University N/A
Human: A204 ATCC HTB-82
Human: G401 ATCC CRL-1441
Human: G402 ATCC CRL-1440
Human: SK-N-AS ATCC CRL-2137
Human: SK-N-BE(2) ATCC CRL-2271
Human:T98G Cell Resource Center for Biomedical
Research, Institute of Development
Aging and Cancer, Tohoku University
TKG0471
Human:A172 Cell Resource Center for Biomedical
Research, Institute of Development,




Mouse: NOD/ShiJic-scidJcl CLEA Japan N/A
Oligonucleotides
Oligos for sgRNA, see Table S1 This study and Brunello Library Human CRISPR Knockout Pooled
Library (Brunello)
Primers for quantitative PCR, see Table S4 This study N/A
Oligos for TP53 sgRNA:
CGCTATCTGAGCAGCGCTCA
This study N/A




lentiCRISPR v2 Sanjana et al., 2014 Addgene: #52961
pX330-U6-Chimeric BB-CBh-hSpCas9 Cong et al., 2013 Addgene: #42230
pMYs-IRES-GFP Cell Biolads Cat# RTV-021
pMYs-c-MYC-IRES-GFP This study N/A
pMx-GFP Cell Biolads Cat# VPK-302
pMxs-hOCT4 Takahashi et al., 2007 Addgene: #17217
pMxs-hSOX2 Takahashi et al., 2007 Addgene: #17218
pMxs-hKLF4 Takahashi et al., 2007 Addgene: #17219
pMXs-hc-MYC Takahashi et al., 2007 Addgene: #17220
pCMV-VSV-G Cell Biolads Cat# VPK-302
pMD2.G Addgene Cat# 12259
psPAX2 Addgene Cat# 12260
Software and Algorithms
GSEA software (version 3.0) Subramanian et al., 2005 http://software.broadinstitute.org/gsea/
index.jsp
DAVID bioinformatics database website Huang et al., 2009 https://david.ncifcrf.gov/home.jsp
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Yasuhiro
Yamada (yasu@ims.u-tokyo.ac.jp).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
All animal experiments were approved by the Animal Experiment Committee at CiRA and IMSUT, and the care of the animals was in
accordance with institutional guidelines. All mice used for the present study were on NOD/ShiJic-scidJcl (NOD SCID) mice of both
sexes (8-10weeks). NODSCIDmicewere purchased fromCLEA Japan, Inc.Micewere kept in the animal facility with 12 hours of light
and dark cycle with food and water ad libitum.
Cell culture and neural induction
201B7 and 1383D6 hiPSCs (provided by Masato Nakagawa, CiRA) were cultured in StemFit AK03N or AK02N (Ajinomoto) on cell
culture plates coated with laminin-511 (Wako) at 37C with 5% CO2. For neural induction, culture medium was switched to GIBCO
PSC Neural Induction Medium (Life Technologies) containing Neurobasal medium and GIBCO PSC neural induction supplement. At
day 7 of the neural induction, these cells were dissociated and plated in neural expansion medium containing 50% Neurobasal
medium, 50% Advanced DMEM/F12 and neural induction supplement. Cells were treated with 10 mM ROCK inhibitor Y27632
(Wako) at the time of plating overnight to prevent cell death. To further induce differentiation, culture medium was switched to
Neurobasal medium containing 2% B-27 Supplement (GIBCO) and GlutaMAX Supplement (GIBCO).
KUP-ATRT-1, an AT/RT cell line, was established at Kyoto University. Other tumor cell lines were purchased from ATCC or Cell
Resource Center for Biomedical Research, Institute of Development, Aging and Cancer, Tohoku University. Tumor cells were
cultured with RPMI 1640 (GIBCO) or MEM, GlutaMAXTM supplement (GIBCO) containing 10% fetal bovine serum (FBS) at 37C
with 5% CO2.
Establishment of hiPSC SMARCB1/; TP53/ -derived cancer cell line
A block of hiPSC SMARCB1/; TP53/-derived tumor was mechanically minced. The minced tissue was digested with StemPro
Accutase Cell Dissociation Reagent (GIBCO) at 37C for 15 minutes. After washing, the tissue was triturated and passed through
a 100 mm cell strainer. Cells were plated onto cell culture plates coated with laminin-511 in AK03N media. Passaging of the cultures
was performed approximately once a week.
METHOD DETAILS
TP53 and SMARCB1 knockout using CRISPR/Cas9 system
The TP53 and SMARCB1 genes were knocked-out with P3 primary cell 4D-Nucleofector X Kit (Lonza). 201B7 cells were transfected
with modified pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid (Addgene: Plasmid #42230) (Cong et al., 2013) expressing a sgRNA
against TP53 (CGCTATCTGAGCAGCGCTCA) or SMARCB1 (TGAGAACGCATCTCAGCCCG) with puromycin-resistance gene.
To avoid genomic integration, puromycin selection (1 ml/ml) was performed only for two days. Each single colony was picked-up
and expanded. The knockout for TP53 and SMARCB1 was confirmed by sequencing and western blot.
Retroviral transduction
To generate retroviral vectors, Plat-GP cells on 150 mm dishes were cultured with DMEM containing 100 U/ml penicillin, 100 m g/ml
streptomycin (P/S) (Nacalai tesque) and 10%FBS (GIBCO) until 70%–80% confluency andwere transfected with 12.375 mg retroviral
Continued
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Wong et al., 2008 http://software.broadinstitute.org/gsea/
msigdb/cards/WONG_EMBRYONIC_
STEM_CELL_CORE
Gene set: hESC-like module Wong et al., 2008 Table S5
Gene set: Core Human module Kim et al., 2010 Table S3
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vector plasmid (pMx-GFP, pMxs-hOCT4, pMxs-hSOX2, pMxs-hKLF4, pMxs-hc-MYC and pMYs-IRES-GFP or pMYs-hc-MYC-
IRES-GFP) (Addgene, Cell Biolabs, Inc.) (Takahashi et al., 2007) independently in combination with 5.625 mg pCMV-VSV-G
(Cell Biolabs, Inc.) using Lipofectamin 2000 (Life technologies). 24 hours after the transfection, the culture media was
refreshed, and the supernatant was collected over 3 consecutive days. The filtered supernatant was concentrated by PEG-it (System
Biosciences), re-suspended, aliquoted and stored at 80C. 1 3 106 of NPLCsSMARCB1/; TP53/ or PSA-NCAM-positive
NPLCsTP53/; SMARCB1/ were incubated with the concentrated virus-containing supernatant overnight. Five days after the
infection, cells were harvested and transplanted into the mouse brain. At the same time, RNA was extracted from the infected cells.
Xenograft tumor model
1 ml of 43 105 cells were injected into the left striatum of NOD SCID mice at the coordinates of 1.5 mm lateral from the bregma and
2mmdeep from the dura using a 10 ml Hamilton syringe with a flow rate of 1 ml per minute. MRI studies were performed on a 1.5-Tesla
MRI scanner (MRmini SA1508; DS Pharma Biomedical). Transplanted mice were traced until they died or showed some neurological
signs (observation period: 4-31weeks).
Histological analysis and immunostaining
Mice were transcardially perfused with 1 3 PBS followed by 4% paraformaldehyde. Following dissection, brain tissues were trans-
ferred to PBS and subsequently embedded in paraffin and sectioned. Sections were stained with hematoxylin and eosin (H&E), and
serial sections were used for the immunohistochemical analysis. The primary antibodies, which were incubated at 4C overnight in
blocking buffer, were as follows: anti-SALL4 (Abnova: #clone 6E3), anti-LIN28A (Cell Signaling Technology: #8706), anti-LIN28B
(Cell Signaling Technology: #5422), anti-Ki67 (SP6) (Abcam: #ab16667), anti-INI1/SNF5 (Sigma-Aldrich: #91735), anti-Vimentin
(V9) (SantaCruz: #sc-6260), anti-GFAP (DAKO: #IR524), anti-CD99 (DAKO: #clone 12E7), anti-S100 (DAKO: #GA504), anti-EMA
(Novocastra: #NCL-L-EMA), anti-SMA (Nichirei: #clone1A4) and anti-Synaptophysin (Nichirei: #clone27G12). The sections were
incubated with the appropriate species of HRP-conjugated secondary antibodies (Nichirei, Histofine) at room temperature for
30 minutes, and chromogen development was performed using DAB (Nichirei). The stained slides were counterstained with Meyer
hematoxylin. The histopathological sections were reviewed by two different pathologists (Yo Y and Ya Y) who have been certified
by the Japanese Society of Pathology.
Immunofluorescent staining
The samples were fixed with 4% paraformaldehyde for five minutes and soaked in PBS. They were then incubated with anti-NESTIN
(Millipore: #MAB5326) at 4C overnight in blocking buffer and were processed with3 500 DAPI (Invitrogen) and3 150 fluorescence-
labeled secondary antibodies diluted with 0.5% BSA in PBS for 90 minutes at room temperature. After washing in PBS for 5 minutes
twice, the samples were mounted and evaluated with a confocal laser-scanning microscope (Zeiss LSM700 or 710).
Western blot analysis
Cell lysates were prepared in RIPA buffer with protease inhibitors. Protein samples were carried out according to standard
methods. The primary antibodies used were anti-INI1/SNF5 (Sigma-Aldrich: #91735), anti-TP53 (Santa Cruz Biotechnology: #sc-126)
and anti-b-actin (Santa Cruz, sc-47778). The secondary antibodies used were ECL anti-mouse IgG, HRP-linked whole antibody
from sheep (NA931, GE Healthcare), ECL anti-rabbit IgG and HRP-linked whole antibody from donkey (NA934, GE Healthcare).
ImageQuant LAS4000 (GE Healthcare) was used for band detection.
Magnetic-based cell sorting (MACS) and flow cytometric analysis
Expanded NPLCsSMARCB1/; TP53/ were exposed to 10 mM of Y27632 (Wako) for more than one hour to prevent cell death prior
to the MACS procedure. After dissociation, the cells were briefly blocked in 0.5% BSA-PBS solution and then incubated with
anti-PSA-NCAMantibody conjugatedwithmicrobeads (Miltenyi Biotec: #130-92-981) for 15minutes at 4C. After extensivewashing,
the cell suspension was loaded on a separation column (LS column) that was attached to a magnetic stand. Positively-labeled cells
that remained in the column were eluted to a tube with culture medium for further manipulation and analysis. After magnetic cell
separation, we further used flow cytometry to examine the purity of PSA-NCAM-positive cells. MACS-sorted cells were cultured
for 24 hours and stained with anti-PSA-NCAM antibody (Millipore: #MAB5324) for 15 minutes at 4C followed by CF488-conjugated
secondary antibody for 10 minutes at 4C. The positive fraction was evaluated by flow cytometry (Aria II, BD) using non-stained cells
as a control.
Genetic screening with lentiviral CRISPR/Cas9 system
We utilized the lentiCRISPR v2 (Addgene #52961) (Sanjana et al., 2014) for one-by-one gene disruption. The candidate genes were
selected based on the previous literatures and databases (Table S1). The lentiviral vector has both a sgRNA scaffold and a Cas9 to
induce insertions and deletions (indels) at the genomic locus of the cells into which they are transduced.
The lentiviral cloning and production were performed as described previously (Sanjana et al., 2014). Briefly, the complementary
oligonucleotides for sgRNAs (Table S1) were annealed by heating to 95C for 3minutes and subsequent cooling to 60C for 3minutes
on ice. The lentiCRISPR v2 plasmid was digested with BsmBI (New England Biolabs) at 55C overnight and purified by FastGene
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Gel/PCR Extraction Kit (Genetics). The annealed oligonucleotides were ligated into the digested lentiCRISPR v2 plasmid by Ligation
high Ver.2 (TOYOBO) at 16C for 30minutes. The reactants were transformed into Stbl3 chemically competent E. coli (Thermo Fisher
Scientific). The grown colonies were analyzed by Sanger sequencing with ABI 3500xL (Applied Biosystems) to confirm correctly
recombined clones. The lentiviral plasmids were extracted by GenElute Plasmid Miniprep Kit (Sigma).
To generate lentivirual vectors, HEK293T cells on 60 mm dishes were cultured with DMEM containing 100 U/ml penicillin,
100 mg/ml streptomycin (P/S) (Nacalai tesque), 10% FBS (GIBCO) until 70%–80% confluency and transfected with 2.4 mg lenti-
CRISPR v2 plasmid, 0.8 mg pMD2.G (Addgene #12259) and 1.6 mg psPAX2 (Addgene #12260) using PEImax (Polysciences). 24 hours
after transfection, culturemedia were refreshed, and the supernatant was collected over 3 consecutive days. The filtered supernatant
was concentrated by PEG-it (System Biosciences), re-suspended, aliquoted and stored at 80C. No lentiviral functional titration
was performed. Instead, we measured base-line cell viability at days 3-5 during the screening process to adjust the transduction
efficiency bias as explained below. The screening was performed with 96-well plate format in duplicate. Each cell line was plated
to be 70%–80% confluent at the day of lentiviral transduction (day 0). We avoided using outer lanes, where the value could be
variable because of the media evaporation. At day 0, virus-containing supernatant was added to each well, and 24 hours later,
puromycin was added to eliminate non-transfected cells. At days 3-5, the baseline cell viability was assessed using alamarBlue
(Bio-Rad). Fluorescence was detected with 2104 EnVision Multi Detection Microplate Reader (Perkin Elmer). The average fluores-
cence intensity value in blank wells was subtracted to determine the fluorescence intensity value of each well. Media were replaced
every 2-3 days. When wells transduced with non-targeting control (NTC) sgRNA reached 70%–80% confluency, cell viability was
measured again by alamarBlue to assess the effect of each knockout on cell growth. Cell growth rates were calculated as follows:
the average of duplicate fluorescence intensity values was divided by the average at baseline. Cell growth rates were compared with
NTC sgRNA-transduced cells.
To confirm the CRISPR/Cas9-mediated cleavage efficiency in this screening, we randomly selected 20 genes among the candi-
date genes and assessed the indel frequency at days 3 and 7 in the SK-N-BE(2) cell line. The indel frequency was calculated by TIDE
software (https://tide.nki.nl) (Brinkman et al., 2014). The TIDE software parameters used in this study were as follows: left boundary,
100 bp; right boundary, 10 bp; decomposition window, 115-685 bp; indel size range, 20 bp.
The titration of puromycin was pre-determined for each cell line to efficiently eliminate non-transduced cells at days 3-5. The
concentrations of puromycin used in this study were 1.0, 1.0 and 1.5 mg/ml for hiPSC SMARCB1/; TP53/-derived cancer cell line,
SK-N-BE(2) and SK-N-AS, respectively.
Cell growth inhibition assays and cell proliferation assays
In vitro drug sensitivity was determined using alamarBlue cell viability reagent (Bio-Rad) according to the manufacturer’s protocol.
Cells were plated into 96-well culture plates at a density of 2 3 103 cells/well. Cells were treated with 10 mM of DMSO, GSK126,
PCI34051 or a combination of GSK126 and PCI34051 at day 0 and incubated for 7 days. The experiment was performed in triplicate,
and each sample was measured three times. Fluorescence intensity was detected with 2104 EnVision Multi Detection Microplate
Reader. The average fluorescence intensity value of blank wells was subtracted to determine the fluorescence intensity of each
well at each time point. The average fluorescence intensity of DMSO-treated cells at day 7 was set to 1. Cell Counting Kit-8 (Dojindo)
was also used to examine in vitro cell proliferation. Abosrbancewasmeasured using iMarkMicroplate Absorbance Reader (Bio-Rad).
siRNA transfection
siRNA transfection was performed using Lipofectamine RNAi Max (Invitrogen). We performed knockdown assays with a siRNA
targeting RAD21 (Dharmacon). Nontargeting siRNA (Dharmacon) was used as a control. Culture medium was exchanged every
2 days, and cell proliferation was determined using Cell Counting Kit-8 (Dojindo).
RNA Preparation, qRT-PCR and microarray analysis
Total RNA was isolated using the RNeasy Plus Mini kit (QIAGEN). The qRT-PCR analysis was performed using GoTaq qPCR Mas-
ter Mix (Promege). The specific primer pairs used for amplification are shown in Table S4. The transcript levels were normalized
to the GAPDH level. The microarray analysis was performed using Human Gene 1.0 ST Array (Affymetrix) in accordance
with the manufacturer’s instructions, GeneSpring GX software program (version 12; Agilent Technology), GSEA software
(version 3.0) and the DAVID bioinformatics database website (https://david.ncifcrf.gov/home.jsp). The gene sets of the hESC-
like module (Wong et al., 2008) and the Core Human module (Kim et al., 2010) were used for the clustering analysis. The gene
set of ‘‘WONG_EMBRYONIC_STEM_CELL_CORE’’ in MSigDB (version 6.0) was used for the GSEA analysis.
Library preparation for RNA sequencing
200 ng of total RNA was prepared for the library construction. High-quality RNA (RNA Integrity Number value R 7) assessed by
Bioanalyzer was used for the library preparation. RNA-seq libraries were generated using the Truseq Stranded mRNA LT sample
prep kit (Illumina). PolyA-containing mRNA was purified by poly-T oligo-attached magnetic beads, and the RNA was fragmented
and primed for cDNA synthesis. Cleaved RNA fragments were reverse transcribed into first strand cDNA using transcriptase and
random primers. Second strand cDNA was synthesized by the incorporation of dUTP, and ds cDNA was separated using AMPure
XP beads (BECKMAN COULTER). A single ‘A’ nucleotide was added to the 30 ends of the blunt fragments, and then adapters with
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index were ligated to the ends of the ds cDNA. ds cDNA fragments were amplified by PCR with PCR primer Cocktail. The number of
PCR cycles was minimized (15 cycles) to avoid skewing the representation of the libraries. RNA-seq libraries were sequenced on
NextSeq 500 (75 bp or 86 bp single, Illumina).
RNA-seq data analyses
The sequenced reads were mapped to the human reference genome (hg38) using Tophat2 (version 2.1.1) with the GENCODE
(version 27) annotation gtf file and the aligner Bowtie2-2.3.4 (Langmead and Salzberg, 2012) after trimming adaptor sequences
and low-quality bases by cutadapt-1.16 (Martin, 2011). The uniquely mapped reads were used for further analyses. Using
cufflinks-2.2.1 (Trapnell et al., 2010) with the human GENCODE (version 27, protein coding) annotation gtf file, reads per kilobase
of exon per million mapped reads (RPKM) were calculated as the expression levels of each gene. RPKM values were used for the
GSEA method.
DNA methylation analyses for infinium methylation array data
Infinium450K data were obtained fromGSE60821 (hESC), GSE92462 (hESC, NSCs, normal brain and fetal brain), GSE36278 (normal
brain, fetal brain and GBM), GSE75153 (MB), GSE73801 (ETMR) and GSE70460 (AT/RT). Previously described human CGIs (Illing-
worth et al., 2010) were used for the methylation analysis. The UCSC LiftOver tools (http://genome.ucsc.edu/) (Rosenbloom et al.,
2015) were used to convert the coordinates of hg18 assembly into those of hg19 assembly. After the conversion of the CGI regions,
overlap regions were merged into a single region. The UCSC refGene table was used to determine the TSS sites. The median signal
value of the probes within each CGI and TSS ± 1,500 bp was calculated as the methylation signal of the region. Brain-methylated
regions and brain-unmethylated regions were defined as the CGI and TSS ± 1,500 bp that represent higher (> 0.6) and lower
(< 0.6) brain-methylation (median methylation signals in 7 brain samples), respectively, compared to PSC-methylation (median
methylation signals in 6 PSC samples). The all probe methylation signals within the indicated regions were used in violin plots.
Quantification and Statistical Analysis
To quantify the dominance of rhabdoid cells in tumors, an H&E stained section was randomly photographed at 10 3magnification.
Three or 4 pictures for each sample were processed with ImageJ software (NIH) to evaluate the positive area of rhabdoid cells. The
positive area was determined by the area of rhabdoid cells divided by the area of the tumor in the histological image. To assess
SALL4-positive cells, each section was randomly photographed at 2003magnification. Positive nuclei in tumor cells were counted
using five images. The number of positive nucleus was divided by the number of total nuclei of tumor cells in each image. These re-
sults were evaluated with Graphpad Prism 6 software.
All values and graphs are expressed as the mean with 95% confidence interval or the median with interquartile range, and statis-
tical analyses were performed using unpaired t test with Welch’s correction or Mann-Whitney U test for continuous variables and
Fisher’s exact test for categorical variables. One-way ANOVA or Kruskal-Wallis test was performed to compare multiple groups.
Dunnett’s or Dunn’s multiple comparisons test was used for multiple comparisons. Kaplan-Meier survival curves were compared
using the log-rank test. Statistical parameters including statistical significance and n values are described in the figures and figure
legends. A value of p < 0.05 was considered significant. All analyses were conducted using Graphpad Prism 6 software.
DATA AND SOFTWARE AVAILABILITY
All data analyzed by microarray and RNA-seq have been deposited in the Gene Expression Omnibus (GEO) under accession
numbers GSE118653 and GSE118654.
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Figure S1: Generation of an atypical teratoid/rhabdoid tumor model using hiPSCs lacking SMARCB1, 
related to Figure 1
 Figure S1: Generation of an atypical teratoid/rhabdoid tumor model using hiPSCs lacking 
SMARCB1, related to Figure 1 
(A) A qRT-PCR for pluripotency genes and neural differentiation genes. Data are presented as the mean ± 
SD of biological triplicates. The mean expression level of hiPSCs 201B7 or NPLCs 201B7 was set to 1. 
(B) A qRT-PCR for neuronal differentiation genes after the neuronal differentiation of NPLCs for 7 days. 
Data are presented as the mean ± SD of biological triplicates. The mean expression level of NPLCs 
(differentiation 7 days) was set to 1. 
(C) Gene ontology enrichment analysis of NPLCs SMARCB1-/-; TP53-/- compared to undifferentiated hiPSCs 
SMARCB1-/-; TP53-/-. Analysis was performed using DAVID (Huang da et al., 2009). Genes showing ≥ 2-fold 
changes in NPLCs SMARCB1-/-; TP53-/- compared to hiPSCs TP53-/-; SMARCB1-/- were used in the analysis. 
(D) Cell proliferation assays of hiPSCs and NPLCs. **p<0.01, ***p<0.001 (One-way ANOVA and 
Dunnett's multiple comparisons test). 
(E) Macroscopic tumor incidence after xenograft transplantation of hiPSCs and NPLCs into the brain of 
immunocompromised mice. 
(F) Microscopic tumor incidence after xenograft transplantation of hiPSCs and NPLCs into the brain of 
immunocompromised mice. 
(G) Representative histological images of microscopic tumors. The iPSC 201B7-derived tumor exhibits a 
teratoma-like histology, which contains ciliated epithelial cells (left), while the NPLCs TP53-/--tumor shows 
a scar-like histology (right). Scale bars, 500 µm (top) and 50 µm (bottom). 
(H) Western blot analysis of 1383D6 iPSCs SMARCB1-/- for SMARCB1 and β-actin shows the lack of 
SMARCB1 in 1383D6 iPSCs SMARCB1-/-.  
(I) Representative histological images of a 1383D6 iPSC SMARCB1-/--derived tumor and 1383D6 NPLC 
SMARCB1-/--derived tumor. Note that the 1383D6 iPSC SMARCB1-/--derived tumor contains rhabdoid cells. 
Scale bars, 500 µm (top) and 20 µm (bottom). 
(J) Quantification of the rhabdoid area within 1383D6 iPSC SMARCB1-/--derived tumors and 1383D6 NPLC 
SMARCB1-/--derived tumors. Data are represented as the median with interquartile range. *p<0.05 (Mann-
















































































































































































































Figure S2: Induction of the ESC-like signature leads to rhabdoid phenotype in tumors, related to Figure 2
 Figure S2: Induction of the ESC-like signature leads to rhabdoid phenotype in tumors, related to 
Figure 2  
(A) A schematic illustration of a xenograft transplantation study of NPLCs SMARCB1-/-; TP53-/- transduced with 
GFP (GFP-NPLCs) or four reprogramming factors (OCT4, SOX2, KLF4 and c-MYC) (OSKM-NPLCs). 
(B) A flow cytometric analysis of PSA-NCAM expression in NPLCs SMARCB1-/-; TP53-/- after sorting with 
PSA-NCAM antibody by magnetic activated cell sorting (MACS). 
(C) A qRT-PCR for OCT4, SOX2, KLF4 and c-MYC at 5 days after the transduction of GFP or OSKM in 
NPLCs SMARCB1-/-; TP53-/-. Data are presented as the mean of technical triplicates. The mean expression level 
of OSKM-NPLCs was set to 1. 
(D) A qRT-PCR for pluripotent genes and neural differentiation genes at 5 days after the transduction of 
GFP, c-MYC or OSKM in NPLCs SMARCB1-/-; TP53-/- in vitro. Data are presented as the mean of three 
biological replicates with standard deviation. The mean expression level of GFP-NPLCs was set to 1. 
*p<0.05, **p<0.01 (One-way ANOVA and Dunnett's multiple comparisons test). 
(E) (F) Survival curve of mice transplanted with GFP-NPLCs or OSKM-NPLCs. Note that mice 
inoculated with OSKM-NPLCs exhibit poor survival when compared to mice inoculated with control 






















































































































Figure S3: c-MYC induces activation of the ESC-like signature and drives rhabdoid tumors in vivo, 
related to Figure 3
 Figure S3: c-MYC induces activation of the ESC-like signature and drives rhabdoid tumors in vivo, 
related to Figure 3 
(A) A schematic illustration of a xenograft transplantation study of NPLCs SMARCB1-/-; TP53-/- transduced with 
GFP (GFP-NPLCs) or c-MYC (MYC-NPLCs). Control GFP-NPLCs are the same as Figure S2. 
(B) A qRT-PCR for c-MYC after the transduction of GFP or c-MYC in NPLCs SMARCB1-/-; TP53-/-. Data are 
presented as the mean of technical triplicates. The mean expression level of MYC-NPLCs was set to 1. 
(C) Representative histological images of a MYC-NPLC-derived tumor. Note that a number of rhabdoid 
cells are observed in the tumor. Scale bars, 500 µm (upper) and 20 µm (lower). 
(D) Quantification of the rhabdoid area in GFP-NPLC- and MYC-NPLC-derived tumors. Data are 
represented as the median with interquartile range. **p<0.01 (Mann-Whitney U test). 
(E) Survival curves of mice transplanted with GFP-NPLCs or MYC-NPLCs. Note that the overall 
survival of mice inoculated with MYC-NPLCs is significantly shorter than of control. Kaplan-Meier 
analysis was performed. ****p<0.0001 (Log-rank test). 
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Figure S4: Human AT/RT specimens exhibit activation of the ESC-like gene expression signature, 
related to Figure 4
 Figure S4: Human AT/RT specimens exhibit activation of the ESC-like gene expression signature, 
related to Figure 4 
(A) Clustering analysis using microarray data revealed that both hESC-like module genes (left) and ESC 
Core module genes (right) are similarly expressed in AT/RT samples and ESCs/iPSCs. Note that some 
ETMRs were clustered with AT/RT samples and ESCs/iPSCs. Medulloblastoma (MB) and glioblastoma 
(GBM) samples are basically clustered separately from ESCs/iPSCs. The microarray data of hPSCs, 
AT/RTs, ETMRs, medulloblastomas and glioblastomas were obtained from GSE22392 (hESC/hiPSC), 
GSE73038 (ETMR), GSE70678 (AT/RT), GSE37418 (MB) and GSE53733 (GBM). 
(B) Immunohistochemical analysis of SALL4, LIN28A and LIN28B in clinical AT/RT specimens. Scale 
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Figure S5: DNA methylation landscape in human AT/RT specimens, related to Figure 4
 Figure S5: DNA methylation landscape in human AT/RT specimens, related to Figure 4 
The DNA methylation landscape in AT/RTs analyzed using Infinium450K data. In this analysis, we first 
extracted differentially methylated CpG sites within CGIs (left) or around TSSs (right) between hPSCs 
and adult brains. hPSC-specific methylated CpG sites and adult brain-specific methylated CpG sites were 
analyzed for AT/RTs, ETMRs, medulloblastomas and glioblastomas as well as fetal brains and NSCs. 
AT/RTs harbor increased methylation at the PSC-specific methylated CpG sites, while adult brain-specific 
methylated CpG sites are less methylated in AT/RTs. Each dot indicates the median of DNA methylation 
at the analyzed CpG sites. Infinium450K data of hPSCs, normal brains, fetal brains, NSCs, AT/RTs, 
ETMRs, medulloblastomas and glioblasomas were obtained from GSE60821 (hPSC), GSE92462 
(hPSC/NSC/normal brain/fetal brain), GSE36278 (normal brain/fetal brain/GBM), GSE73801 (ETMR), 























































Figure S6: Pediatric cancers exhibit activation of the ESC-like gene expression signature, related to Figure 5
 Figure S6: Pediatric cancers exhibit activation of the ESC-like gene expression signature, related to 
Figure 5 
Principal component analysis of the global gene expression profiles in pediatric cancers and adult 
cancers. Pediatric cancers exhibit ESC-like gene expression patterns when compared to the corresponding 
adult cancers. AT/RT: atypical teratoid/rhabdoid tumor, NB: neuroblastoma, WT: Wilms tumor, HB: 
hepatoblastoma, GBM: glioblastoma, ACC: adrenocortical carcinoma, RCC: renal cell carcinoma, HCC: 
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Figure S7: Genetic screening with CRISPR/Cas9 to develop a novel therapeutic strategy for AT/RT, 
related to Figure 6
 Figure S7: Genetic screening with CRISPR/Cas9 to develop a novel therapeutic strategy for AT/RT, 
related to Figure 6 
(A) The cleavage efficiency at Day 3 and Day 7 after lentiviral-mediated transduction of CRISPR/Cas9 
together with sgRNAs in SK-N-BE(2) in vitro. sgRNAs for 18 randomly selected genes were transduced 
with CRISPR/Cas9, and the efficiency of non-homologous end joining was measured by TIDE software 3 
and 7 days after the lentiviral transduction. Data are represented as the median with interquartile range. 
(B) GSEA showing that EZH2 inhibition by GSK126 suppresses the ESC-like module in hiPSC-derived 
cancer cells. 
(C) Growth ratios (Day 14/Day 3) of hiPSC-derived cancer cells, SK-N-AS and SK-N-BE(2) transduced 
with CRISPR/Cas9 with sgRNA for non-targeting control (NTC) or RAD21. Two independent sgRNAs 
for RAD21 reduced the cell growth ratio compared to NTC. Data are presented as the mean of three 
biological replicates with standard deviation. The growth ratio of NTC-transduced cells was set to 1. 
*p<0.05, **p<0.01 and ****p<0.0001 (One-way ANOVA and Dunnett's multiple comparisons test). 
(D) Cell viability of hiPSC-derived cancer cells treated with PCI34051 (10 µM) or the combination of 
PCI34051 (10 µM) and siRAD21. Note that the growth inhibitory effect of PCI34051 is not obvious in the 
presence of siRAD21. *p<0.05, ****p<0.0001 (One-way ANOVA and Dunnett's multiple comparisons 
test). 
(E) GSEA revealed that suppression of the ESC-like module by GSK126 is further pronounced by the 
combination treatment of GSK126 and PCI34051. 
(F) Sole inhibition of HDAC8 by PCI34051 does not suppress the ESC-like module in hiPSC-derived 
cancer cells. 
(G) Cell viability of glioblastoma cell lines treated with DMSO, PCI34051 (10 µM), GSK126 (10 µM) or 
the combination of PCI34051 and GSK126 (10 µM each). *p<0.05, ***p<0.001 (One-way ANOVA and 
Dunnett's multiple comparisons test). 
 
Table S1: List of 110 target genes and their oligos for sgRNA, related to Figure 6
Tagert genes associated with the





















































































































































































































































































































































Table S2: References for picking out 110 target genes, related to Figure 6
First author Reference
Doench JG Nat Biotechnol. 2016, 34(2):184-191
Kim J Cell. 2010, 143(2):313-24
Takahashi K Cell. 2016, 126(4):663-76
Veschi V Cancer Cell. 2017, 31(1):50-63
Zhang K Clin Cancer Res. 2014, 20(5):1179-89
Kaur H J Neuropathol Exp Neurol. 2015, 74(2):177-85
Alimova I Neuro Oncol. 2013, 15(2):149-60
Fazzio TG Cell. 2008, 134(1):162-74
Young RA Cell. 2011, 144(6):940-54
Urbach A Genes Dev. 2014, 1;28(9):971-82
Molenaar JJ Nat Genet. 2012, 44(11):1199-206
Chia NY Nature. 2010, 468(7321):316-20
Hu G Genes Dev. 2009, 23(7):837-48
Abujarour R Stem Cells. 2010, 28(9):1487-97
Weingart MF Oncotarget. 2015, 6(5):3165-77
Sanjana NE Nat Methods. 2014, 11(8):783-4
Collinson A Cell Rep. 2016, 17(10):2700-14




compared to contorol SD Rank Gene Name
Relative growth ratio
compared to contorol SD Rank Gene Name
Relative growth ratio
compared to contorol SD
1 FN1 0.473713218 0.064243312 1 EIF4A3 0.169565387 0.009805383 1 MYCN 0.30760042 0.006681813
2 IFITM2 0.601700671 0.079338947 2 INCENP 0.527787752 0.013365749 2 SUPT16H 0.348697118 0.04708912
3 PRAME 0.624056884 0.104260527 3 DDX47 0.644558025 0.007870972 3 EIF4A3 0.41083802 0.025312479
4 SETD8 0.630024573 0.032886971 4 MCM7 0.66923558 0.016852987 4 SETDB1 0.525616952 0.058120662
5 SNRPD2 0.684795705 0.067667121 5 WDR82 0.675463706 0.03716815 5 DDX47 0.673008303 0.004742421
6 SMC4 0.699734173 0.130264191 6 LUC7L3 0.683279843 0.014687562 6 RAD21 0.67591018 0.089722782
7 C1QB 0.721125506 0.027325322 7 PHOX2B 0.68995379 0.008922695 7 TIMP2 0.698883957 0.047643183
8 TCF3 0.737204194 0.017689598 8 CDC5L 0.693336429 0.005673633 8 CDC5L 0.755521981 0.034751615
9 EZH2 0.743813879 0.031221687 9 SNRPD2 0.696611714 0.034632283 9 LUC7L3 0.768067499 0.081317428
10 MYCN 0.74718664 0.049478903 10 CHAF1A 0.702607795 0.055870782 10 EZH2 0.797878906 0.091969876
11 EIF4A3 0.764182888 0.049226373 11 SSRP1 0.716823563 0.036719143 11 SMC1A 0.800888766 0.043694774
12 IFITM1 0.777677083 0.011620789 12 EYA2 0.732362823 0.07205275 12 MCM6 0.807855081 0.044683803
13 MAP4K4 0.77853271 0.038224403 13 TPR 0.737353215 0.028882318 13 YY1 0.819126043 0.022523618
14 GLUL 0.778803996 0.071004748 14 RAD21 0.747631663 0.121261803 14 SNRPD2 0.829977136 0.042859664
15 JARID2 0.790290675 0.039910139 15 DHX15 0.755507112 0.075774477 15 RTF1 0.83448445 0.084633429
16 ETV5 0.803919269 0.052786473 16 C1QB 0.765545571 0.037311765 16 THAP11 0.839345055 0.045945844
17 MYBL2 0.812490684 0.008053099 17 MCM6 0.770667755 0.034568063 17 FUBP1 0.841668009 0.044114001
18 UCK2 0.832108769 0.055738043 18 DST 0.779968272 0.046493809 18 EED 0.850379696 0.060952255
19 APOC1 0.835838286 0.035569568 19 NANOG 0.7852302 0.124220033 19 DHX15 0.859217002 0.051654761
20 BCL11A 0.836508025 0.051817538 20 RTF1 0.788666151 0.018072722 20 SETD8 0.872510077 0.05216399
21 KLF9 0.847305588 0.054453079 21 SMC1A 0.804984617 0.073380992 21 TPR 0.881572011 0.014919359
22 RAD21 0.851195014 0.060688001 22 MYC 0.80943862 0.012560515 22 MCM7 0.891909855 0.095691889
23 HNRNPUL1 0.859588338 0.008848117 23 NFKBIA 0.814613849 0.072556011 23 WDR82 0.90256298 0.020174874
24 HLA-DPA1 0.862452736 0.065881531 24 IFITM2 0.814791199 0.022504999 24 MYBL2 0.914257653 0.046015055
25 CAMK2N1 0.865428957 0.051593928 25 SOX2 0.820547874 0.050932206 25 SMC4 0.920549927 0.071579455
26 EYA2 0.866678259 0.047308828 26 MYBL2 0.823530108 0.044051622 26 CRMP1 0.931479687 0.032254534
27 DHX15 0.878604134 0.158983685 27 HMGA1 0.823551052 0.019301681 27 EDF1 0.932464322 0.091600732
28 MYBPH 0.888863478 0.02228249 28 POU5F1 0.834678327 0.07933968 28 LIN28B 0.934563892 0.020976851
29 PLA2G16 0.89124223 0.028606255 29 CRABP2 0.837321721 0.009594555 29 ANP32A 0.940729803 0.032435559
30 SLC15A1 0.893447815 0.044758462 30 THAP11 0.840812994 0.021677715 30 MGA 0.94145195 0.123114295
31 NIPBL 0.898832048 0.011430032 31 TRIM28 0.840892971 0.097667164 31 TRIM28 0.950994798 0.023134902
32 TCF4 0.913598879 0.003228589 32 SUPT16H 0.84338783 0.041601944 32 HMGA1 0.966226807 0.104183429
33 POU5F1 0.913767301 0.03421047 33 EED 0.845130685 0.040163579 33 SMAD3 0.97201216 0.182632686
34 CRABP2 0.916729641 0.088531672 34 LIN28B 0.85108255 0.135128323 34 CHD1 0.975064385 0.10105166
35 CENPE 0.917613413 0.004209638 35 CAMK2N1 0.874436434 0.021487793 35 ZNF136 0.998032135 0.349278622
36 FOXM1 0.922542682 0.040502371 36 CENPE 0.875624545 0.054640938 36 hNTC 1 0.074491065
37 SOX11 0.923229395 0.009800014 37 SETD8 0.877680583 0.057412923 37 GJA1 1.000052694 0.022941246
38 SMC1A 0.923714236 0.063992056 38 YY1 0.879327529 0.033394962 38 CENPE 1.010773235 0.017901575
39 RND2 0.924167105 0.09175922 39 CHD1 0.89024884 0.047361739 39 PAX8 1.012416037 0.045168022
40 THAP11 0.925627053 0.01227535 40 TIMP2 0.910001826 0.019170634 40 SMAD2 1.014108917 0.13944452
41 RGS5 0.934344192 0.034692423 41 SUV39H2 0.911920696 0.068101775 41 PHOX2B 1.015792563 0.025960211
42 INCENP 0.934491407 0.086727669 42 IGF2 0.912607631 0.027133803 42 INCENP 1.018297675 0.033830618
43 TPR 0.937488377 0.030652308 43 IGFBP2 0.925028892 0.093294768 43 MAX 1.019900888 0.031910642
44 SOX2 0.939579377 0.015416376 44 NIPBL 0.926839353 0.069389496 44 IGF2 1.038329382 0.094353461
45 NANOG 0.947840479 0.039180125 45 EDF1 0.940227719 0.087414044 45 SIX2 1.043797056 0.029718442
46 HMGA1 0.956009234 0.016494905 46 CHD7 0.958289333 0.031230682 46 UCK2 1.048853457 0.051709103
47 ENAH 0.958993037 0.02282592 47 PAX2 0.961687727 0.026204026 47 CBX3 1.049024649 0.125173108
48 MYC 0.96444836 0.053700882 48 SMARCA4 0.964495493 0.009502328 48 SSRP1 1.056972145 0.057920072
49 SUV39H2 0.964944735 0.038070788 49 FUBP1 0.964785045 0.029821963 49 CHD7 1.072602867 0.136798827
50 LUC7L3 0.967701384 0.031203097 50 SMC4 0.969079091 0.069771416 50 SUV39H2 1.08837556 0.034538565
51 EYA1 0.973212321 0.037066058 51 ARID1A 0.969262322 0.015790648 51 PAX2 1.090052358 0.013647572
52 SSRP1 0.984356995 0.051497718 52 MAX 0.970574745 0.022727964 52 SOX2 1.095289468 0.087804425
53 E2F7 0.987737046 0.039588074 53 LMO1 0.973947123 0.030277472 53 MSH6_2 1.098389799 0.047546164
54 RTF1 0.992455009 0.008702249 54 RIF1 0.978593715 0.074609039 54 RIF1 1.103591236 0.170667944
55 PAX2 0.99305148 0.018531997 55 SMAD3 0.989914087 0.019388857 55 CDK8 1.109201741 0.087316483
56 ANP32A 0.996628905 0.002767853 56 PAX8 0.992282333 0.059223962 56 HMGA2 1.121950403 0.132672122
57 LIN28B 0.997706827 0.030467343 57 UCK2 0.997291056 0.037441333 57 RGS5 1.124248181 0.038604092
58 hNTC 1 0.03228208 58 SMARCC1 0.998004712 0.029855718 58 CBX1 1.128212499 0.05438669
59 DST 1.001685756 0.044369644 59 PRAME 0.999415342 0.045707195 59 FOXM1 1.144101657 0.024373021
60 GJA1 1.002986873 0.048744042 60 hNTC 1 0.069772848 60 TCF4 1.147873706 0.044177141
61 MCM7 1.009580956 0.038391653 61 SETDB1 1.003438736 0.042353556 61 STAT3 1.151953475 0.183347228
62 PAX8 1.011599431 0.054704041 62 EZH2 1.004972622 0.031265839 62 BCL11A 1.153907184 0.045437751
63 TRIM28 1.015925545 0.052812528 63 CRMP1 1.008382645 0.024593584 63 LMO1 1.154653788 0.091792006
64 IGF2 1.018768979 0.048452086 64 CBX3 1.009179469 0.046725171 64 MTA1 1.155682319 0.071549524
65 CHAF1A 1.019569065 0.053726003 65 ANP32A 1.010391678 0.033761899 65 EYA2 1.161538966 0.044899249
66 DDX47 1.019614249 0.024087719 66 SIX2 1.010971216 0.033826736 66 CHAF1A 1.182820702 0.023513641
67 IGFBP2 1.022850516 0.130331852 67 RGS5 1.015686882 0.012107737 67 GPR64 1.189148551 0.01187839
68 MCM6 1.025198368 0.020890819 68 SMAD2 1.018613596 0.057613405 68 IGFBP2 1.200468476 0.067726241
69 ZNF43 1.026718922 0.014895802 69 FN1 1.019482023 0.043113878 69 POU5F1 1.207771613 0.122413129
70 LMO1 1.027048617 0.022904104 70 MGA 1.032093197 0.05340931 70 ZNF43 1.208109021 0.387610777
71 CBX1 1.028057096 0.092297571 71 CDK8 1.033383322 0.030819523 71 MYC 1.211936704 0.064926536
72 MTA1 1.030018251 0.037264447 72 GJA1 1.035622325 0.065187863 72 NIPBL 1.225542162 0.024078461
73 GPR64 1.030509761 0.030482975 73 MED1 1.052961765 0.023867936 73 DST 1.227785041 0.0883124
74 CRMP1 1.032984939 0.069514021 74 ZNF43 1.056187822 0.057608862 74 H2AFZ 1.235172636 0.122688269
75 CBX3 1.03483747 0.02459842 75 CBX1 1.060030611 0.089459156 75 E2F7 1.240871988 0.082899533
76 SMAD3 1.035063859 0.027596984 76 PLA2G16 1.060361987 0.016154541 76 C1QB 1.250473319 0.09249421
77 RGS4 1.035576599 0.064922005 77 RGS4 1.060911813 0.097107471 77 NANOG 1.259377244 0.114304222
78 SUPT16H 1.039592187 0.011919653 78 MSH6_2 1.061137934 0.040835141 78 NFKBIA 1.260062699 0.045858298
79 PHOX2B 1.047577482 0.014977001 79 ARID4A 1.065230337 0.028242087 79 CAMK2N1 1.268463505 0.021814396
80 MAX 1.049063812 0.01553368 80 H1FX 1.074440737 0.035540789 80 SLC15A1 1.278713428 0.061881934
81 CDK8 1.0503878 0.034368434 81 TCF3 1.085152051 0.154322066 81 MED1 1.303813441 0.022923171
82 SMARCA4 1.050994915 0.007792492 82 H2AFZ 1.088555744 0.025901837 82 ARID1A 1.305570971 0.221027127
83 SIX2 1.055854942 0.040821165 83 ZNF136 1.098326367 0.032473232 83 WHSC1 1.307680009 0.036630042
84 ARID4A 1.057425882 0.011797434 84 GPR64 1.101578418 0.00517393 84 KLF9 1.314040001 0.050674121
85 NFKBIA 1.057981618 0.097235452 85 HMGA2 1.10477116 0.046863576 85 H1FX 1.316887364 0.059939772
86 H2AFZ 1.060835877 0.031733782 86 STAT3 1.106066933 0.03976361 86 SMARCA4 1.329257585 0.557852373
87 MGA 1.061182685 0.033528636 87 FOXM1 1.182992117 0.053552744 87 SOX11 1.331771385 0.107782256
88 SMARCC1 1.063659763 0.018690698 88 APOC1 1.201390586 0.061976176 88 APOC1 1.335807366 0.065179055
89 EED 1.065043176 0.058118364 89 HNRNPUL1 1.211376924 0.03130036 89 GLUL 1.350770148 0.090388672
90 TIMP2 1.066063103 0.032476205 90 IFITM1 1.222479321 0.16351548 90 SMARCC1 1.355346679 0.433879977
91 SMAD2 1.070264506 0.022879782 91 SOX11 1.265689384 0.049950114 91 IFITM2 1.361292041 0.029815603
92 H1FX 1.072841563 0.053793748 92 BCL11A 1.269249166 0.072630455 92 CRABP2 1.38470777 0.231038172
93 CHD7 1.076817451 0.037121991 93 TCF4 1.290443945 0.013844829 93 HNRNPUL1 1.399116379 0.070087878
94 YY1 1.079569319 0.039026623 94 SLC15A1 1.329457088 0.045047255 94 MYBPH 1.400569057 0.149347363
95 FUBP1 1.080830931 0.022007283 95 MAP4K4 1.345945572 0.121853915 95 PLA2G16 1.412178723 0.069008558
96 MSH6 1.081696089 0.019827689 96 WHSC1 1.358066892 0.021668405 96 ARID4A 1.415399709 0.059169761
97 MED1 1.097654637 0.022986743 97 JARID2 1.392056741 0.072347197 97 RGS4 1.424994737 0.070703087
98 CDC5L 1.109372871 0.050598035 98 MTA1 1.411135363 0.130293187 98 HLA-DPA1 1.425461723 0.068160783
99 EDF1 1.110216144 0.051350721 99 MYCN 1.441390666 0.046718904 99 KDM5B 1.428454545 0.054646645
100 ZNF136 1.117405554 0.028086986 100 GLUL 1.442074071 0.083110734 100 ENAH 1.49774191 0.134021268
101 ARID1A 1.119694063 0.031637066 101 E2F7 1.45236403 0.058137901 101 FN1 1.507854005 0.055364462
102 SETDB1 1.120265621 0.02488206 102 ENAH 1.512990909 0.041715052 102 IFITM1 1.593387131 0.021176676
103 RIF1 1.126121047 0.010969745 103 KDM5B 1.518139597 0.051182514 103 JARID2 1.617929905 0.093778484
104 WDR82 1.127288957 0.046816292 104 MYBPH 1.579735763 0.054012904 104 RND2 1.623044227 0.087759961
105 HMGA2 1.141975854 0.046444506 105 ETV5 1.620459123 0.108366003 105 ETV5 1.652729228 0.418006596
106 WHSC1 1.148405364 0.020486602 106 HLA-DPA1 1.744922707 0.158093226 106 EYA1 1.792898283 0.207899864
107 CHD1 1.150064716 0.035342853 107 ETV1 1.755095567 0.049681282 107 ETV1 1.823783525 0.054252776
108 STAT3 1.162237302 0.008364431 108 RND2 1.80329171 0.163430477 108 TCF3 1.850068304 0.056942047
109 ETV1 1.219780016 0.128501961 109 HTATIP2 2.087640063 0.186598968 109 MAP4K4 1.890700021 0.087464659
110 HTATIP2 1.24005642 0.026421063 110 KLF9 2.333761653 0.174994017 110 PRAME 1.930211441 0.27164313
111 KDM5B 1.271766098 0.278748792 111 EYA1 2.53060758 0.224590751 111 HTATIP2 1.965732453 0.164307093
hiPSC-derived cancer cells



















Quantitative PCR for transduction of
pMxs-OCT4, SOX2, KLF4 and c-MYC
c-MYC ATACATCCTGTCCGTCCAAGCAGA GACATGGCCTGCCCGGTTATTATT
SOX2 TTCACATGTCCCAGCACTACCAGA GACATGGCCTGCCCGGTTATTATT
KLF4 CCACCTCGCCTTACACATGAAGA GACATGGCCTGCCCGGTTATTATT
OCT4 GCTCTCCCATGCATTCAAACTGA CTTACGCGAAATACGGGCAGACA
Direct sequencing
SMARCB1 CTCGCTGACTGTTGCTTCCA ACGGGACTGTTCCCACGTAA
TP53 TGTGCAGCTGTGGGTTGATT CGCAAATTTCCTTCCACTCG
